AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

NCT05578430 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Resectable Hepatocellular Carcinoma

Interventions

DRUG: Cadonilimab
PROCEDURE: TACE
PROCEDURE: Surgery

Sponsor

Sun Yat-sen University